Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Mesothelioma
Stage/Subtype:  recurrent malignant mesothelioma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-18 of 18 for your search:
Start Over
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02015, CDR0000665415, S0905, U10CA032102, SWOG-S0905, NCT01064648
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110160, 11-C-0160, NCT01362790
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 120111, 12-C-0111, NCT01583686
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TL139204, NCT00685204
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: AAAB9658 (A6), NCT00859495
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AAAD4868, NCT00996385
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 12-0032, NCI-2012-00332, NCT01592383
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VS-6063-202, NCT01870609
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: IRB14-1381, NCI-2015-00348, P30CA014599, NCT02399371
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110041, 11-C-0041, NCT01258868
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-169, NCT01766739
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MpeTK01, NCT01997190
Hyperthermic Thoracic Perfusion (HITEC) for Children, Adolescents and Adults With Sarcomas
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 21
Sponsor: Other
Protocol IDs: 2012-0657, NCI-2014-00510, NCT01998529
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CX-839-001, NCT02071862
CART-meso in Mesothelin Expressing Cancers
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 31213, NCT02159716
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VS-6063-104, NCT02372227
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 15-007, NCT02414269
Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy
Phase: No phase specified
Type: Treatment
Status: Active
Age: 19 and older
Sponsor: NCI, Other
Protocol IDs: 9148, NCI-2014-01468, P30CA015704, NCT02204761
Start Over